Детемир (Левемир): современные парадигмы инсулинотерапии

Особенность структуры молекулы Левемир (детемир), объясняя низкую вариабельность фармакодинамических показателей, определяет более предсказуемый сахароснижающий эффект и меньший риск общих и ночных гипогликемий в различных возрастных группах у пациентов с СД 1-го и 2-го типа, чем при использовании других базальных препаратов инсулина. Помимо этого, инсулин детемир (Левемир) не влияет на массу тела, что объясняется его центральным действием (быстрым проникновением через гематоэнцефалический барьер, регуляцией чувства голода и насыщения, а также улучшением распознавания гипогликемий) и влиянием на синтез гормонов, регулирующих аппетит и энергообмен. Установлены плейотропные эффекты детемира - гепатоселективность, влияние на метаболизм липидов и реабсорбцию натрия.

детемир, низкий риск гипогликемий, плейотропные эффекты

1. Horvath K., Jeitler K., Berghold A., Ebrahim S.H., Gratzer T.W., Plank J., Kaiser T., Pieber T.R., Siebenhofer A. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; 2:CD005613.

2. Carver C. Insulin treatment and the problem of weight gain in type 2 diabetes. Diabet Educ 2006; 32: 910-917.

3. Van Avendonk M.J., Gorter K.J., van den Donk M., Rutten G.E. Insulin therapy in type 2 diabetes is no longer a secondary care activity in the Netherlands. Prim Care Diabet 2009; 3: 1: 23-28.

4. Peyrot M., Skovlund S.E., Landgraf R. Epidemiology and correlates of weight worry in the multinational Diabetes Attitudes, Wishes and Needs study. Curr Med Res Opin. 2009; 25: 8: 1985-1993.

5. Selam J.L., Koenen C., Weng W., Meneghini L. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr Med Res Opin 2008; 24: 1: 11-20.

6. Kurtzhals P. How to achieve a predictable basal insulin? Diabet Metabol 2005; 31: 4: Pt 2: 4S25-4S33.

7. Polonsky K.S., Given B.D., Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988; 81: 2: 442-448.

8. Scholtz H.E., Pretorius S.G., Wessels D.H., Becker R.H. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 2005; 48: 10: 1988-1995.

9. Plank J., Bodenlenz M., Sinner F., Magnes C., Görzer E., Regittnig W., Endahl L.A., Draeger E., Zdravkovic M., Pieber T.R. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabet Care 2005; 28: 5: 1107-1112.

10. Klein O., Lynge J., Endahl L., Damholt B., Nosek L., Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metabol 2007; 9: 3: 290-299.

11. Scholtz H.E., van Niekerk M., Meyer B.H., Rosenkranz B. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using the euglycaemic clamp technique (Abstract). Diabetologia 1999; 42: Suppl 1: A235.

12. Ziel F.H., Davidson M.B., Harris M.D., Rosenberg C.S. The variability in the action of unmodified insulin is more dependent on changes in tissue insulin sensitivity than on insulin absorption. Diabet Med 1988; 5: 7: 662-666.

13. Galloway J.A., Spradlin C.T., Howey D.C., Dupre J. Intrasubject differences in pharmacokinetic and pharmacodynamic responses: the immutable problem of present-day treatment. In: Diabetes. Eds. M. Serrano-Rios, P.J. Lefebvre. New York: Excerpta Medica1986; 877-886.

14. Heinemann L. Variability of insulin absorption and insulin action. Diabet Technol Ther 2002; 4: 5: 673-682.

15. Heinemann L., Weyer C., Rauhaus M., Heinrichs S., Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabet Care 1998; 21: 11: 1910-1914.

16. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obes Relat Metabol Dis 2004; 28: Suppl 2: S23-S28.

17. Kurtzhals P., Schaffer L., Sørensen A., Kristensen C., Jonassen I., Schmid C., Trub T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.

18. Heinemann L., Sinha K., Weyer C., Loftager M., Hirschberger S., Heise T. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 1999; 16: 4: 332-338.

19. Pieber T.R., Plank J., Goerzer E., Sommer R., Wutte A., Sinner F., Bodenlenz M., Endahl L., Draeger E., Zdravkovic M. Duration of action, pharmacodynamic profile and between-subject variability of insulin detemir in subjects with type 1 diabetes (Abstract). Diabetes 2002; 51: Suppl 2: A53.

20. Kurtzhals P., Havelund S., Jonassen I., Ribel U., Markussen J. Mode of action of fatty acid acylated insulin: a novel type of soluble, long-acting insulin analogues (Abstract). Diabetes 1996; 45: Suppl 1: 222A.

21. Levemir (insulin detemir (rDNA origin) injection). Prescribing information. Princeton. New York: Novo Nordisk Inc 2010.

22. Heise T., Nosek L., Rønn B.B., Endahl L., Heinemann L., Kapitza C., Draeger E. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 6: 1614-1620.

23. Strange P., McGill J., Mazzezo M. Reduced pharmacokinetics (PK) variability of a novel, long acting insulin analogue (Abstract). Diabetes 1999; 48: Suppl 1: A103.

24. Heller S., Kim H., Draeger E. Within-person variation in fasting blood glucose is correlated to incidence of hypoglycaemia in people with Type 1 diabetes treated with insulin detemir and NPH insulin (abstract). Diabetologia 2004; 47: Suppl 1: A303.

25. Vague P., Selam J.L., Skeie S., De Leeuw I., Elte J.W., Haahr H., Kristensen A., Draeger E. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabet Care 2003; 26: 590-596.

26. De Leeuw I., Vague P., Selam J.L., Skeie S., Lang H., Draeger E., Elte J.W. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabet Obes Metabol 2005; 7: 73-82.

27. Raslova K., Bogoev M., Raz I., Leth G., Gall M.A., Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabet Res Clin Pract 2004; 66: 193-201.

28. Robertson K.J., Schonle E., Gucev Z., Mordhorst L., Tamer S.C., Gall M.A., Ludvigsson J. Benefits of insulin detemir over NPH insulin in children and adolescents with type 1 diabetes: lower and more predictable fasting plasma glucose and lower risk of nocturnal hypoglycaemia (abstract). Diabetologia 2004; 47: Suppl 1: A32.

29. Bartley P.C., Bogoev M., Larsen J., Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008; 25: 4: 442-449.

30. Garber A.J., Clauson P., Pedersen C.B., Kolendorf K. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials. J Am Geriat Soc 2007; 55: 11: 1735-1740.

31. Robertson K.J., Schoenle E., Gucev Z., Mordhorst L., Gall M.A., Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabet Med 2007; 24: 1: 27-34.

32. Davies M.J., Derezinski T., Pedersen C.B., Clauson P. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabet Technol Ther 2008; 10: 4: 273-277.

33. Hermansen K., Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabet Obes Metabol 2007; 9: 209-217.

34. Riddle M.C., Rosenstock J., Gerich J. Insulin Glargine 4002 Study Investigators: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabet Care 2003; 26: 3080-3086.

35. Fritsche A., Haring H. At last, a weight neural insuline? Int J Obes 2004; 28: Suppl 2: S41-S46.

36. Hermansen K., Davies M., Derezinski T., Martinez Ravn G., Clauson P., Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabet Care 2006; 29: 1269-1274.

37. Home P., Bartley P., Russell-Jones D., Hanaire-Broutin H., Heeg J.E., Abrams P., Landin-Olsson M., Hylleberg B., Lang H., Draeger E. Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabet Care 2004; 27: 1081-1087.

38. Russell-Jones D., Khan R. Insulin-associated weight gain in diabetes: causes, effects and coping strategies. Diabet Obes Metabol 2007; 9: 799-812.

39. Wing R.R., Klein R., Moss S.E. Weight gain associated with improved glycemic control in population-based sample of subjects with type I diabetes. Diabet Care 1990; 13: 1106-1109.

40. Rosenstock J., Davies M., Home P.D., Larsen J., Koenen C., Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408-416.

41. Hopkins D.F., Williams G. Insulin receptors are widely distributed in human brain and bind human and porcine insulin with equal affinity. Diabet Med 1997; 14: 1044-1050.

42. Pliquett R.U., Fuhrer D., Falk S., Zysset S., von Cramon D.Y., Stumvoll M. The effects of insulin on the central nervous system-focus on appetite regulation. Horm Metabol Res 2006; 38: 442-446.

43. Tschritter O., Hennige A.M., Preissl H., Porubska K., Schafer S.A., Lutzenberger W., Machicao F., Birbaumer N., Fritsche A., Haring H.U. Cerebrocortical beta activity in overweight humans responds to insulin detemir. PLoS One 2007; 2:e1196.

44. Rossetti P., Porcellati F., Ricci N.B., Candeloro P., Cioli P., Bolli G.B., Fanelli C.G. Different brain responses to hypoglycemia induced by equipotent doses of the long-acting insulin analog detemir and human regular insulin in humans. Diabetes 2008; 57: 746-756.

45. Tschritter O., Schafer S.A., Klett J., Pfafflin A., Haring H.U., Hennige A.M., Fritsche A. Insulin detemir causes increased symptom awareness during hypoglycaemia compared to human insulin. Diabet Obes Metabol 2009; 11: 1017-1026.

46. Руяткина Л.А., Руяткин Д.С., Березовская Г.А. Гипогликемии в патогенезе сердечно-сосудистого риска. Фарматека 2013; 6: 15-21.

47. Rana O., Byrne C.D., Kerr D., Coppini D.V., Zouwail S., Senior R., Begley J., Walker J.J., Greaves K. Acute hypoglycemia decreases myocardial blood flow reserve in patients with type 1 diabetes mellitus and in healthy humans. Circulation 2011; 124: 14: 1548-1556.

48. Heller S.R. Abnormalities of the electrocardiogram during hypoglycaemia: the cause of the dead in bed syndrome? Int J Clin Pract 2002; 129: Suppl: 27-32.

49. Woods S.C., Seeley R.J., Baskin D.G., Schwartz M.W. Insulin and the blood-brain barrier. Curr Pharm Des 2003; 9: 795-800.

50. Morton G.J., Cummings D.E., Baskin D.G., Barsh G.S., Schwartz M.W. Central nervous system control of food intake and body weight. Nature 2006; 443: 289-295.

51. Woods S.C., Lotter E.C., McKay L.D., Porte D. Jr. Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Nature 1979; 282: 503-505.

52. Benedict C., Kern W., Schultes B., Born J., Hallschmid M. Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J Clin Endocrinol Metabol 2008; 93: 1339-1344.

53. Hallschmid M., Benedict C., Schultes B., Fehm H.L., Born J., Kern W. Intranasal insulin reduces body fat in men but not in women. Diabetes 2004; 53: 3024-3029.

54. Hallschmid M., Schultes B., Marshall L., Molle M., Kern W., Bredthauer J., Fehm H.L., Born J. Transcortical direct current potential shift reflects immediate signaling of systemic insulin to the human brain. Diabetes 2004; 53: 2202-2208.

55. Hallschmid M., Jauch-Chara K., Korn O. et al. Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects. Diabetes 2010; 59: 1101-1107.

56. Zachariah S., Sheldon B., Shojaee-Moradie F., Jackson N.C., Backhouse K., Johnsen S., Jones R.H., Umpleby A.M., Russell-Jones D.L. Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes. Diabet Care 2011; 34: 7: 1487-1491.

57. Brüning J.C., Gautam D., Burks D.J., Gillette J., Schubert M., Orban P.C., Klein R., Krone W., Muller-Wieland D., Kahn C.R. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289: 2122-2125.

58. Tschritter O., Porubska K., Hennige A., Preissl H., Lutzen-Berger W., Fritsche A., Häring H. Neuronal activation of the human cerebral cortex by administration of insulin detemir compared to human insulin (abstract). Diabetologia 2005; 48: Suppl 1: A256.

59. Hennige A.M., Sartorius T., Tschritter O., Preissl H., Fritsche A., Ruth P., Haring H.U. Tissue selectivity of insulin detemir action in vivo. Diabetologia 2006; 49: 1274-1282.

60. Tschritter O., Hennige A.M., Preissl H., Porubska K., Schafer S.A., Lutzenberger W., Machicao F., Birbaumer N., Fritsche A., Haring H.U. Cerebrocortical beta activity in overweight humans responds to insulin detemir. PLoS One 2007; 2: e1196.

61. Kern W., Peters A., Fruehwald-Schultes B., Deininger E., Born J., Fehm H.L. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology 2001; 74: 270-280.

62. Banks W.A., Morley J.E., Lynch J.L., Lynch K.M., Mooradian A.D. Insulin detemir is not transported across the blood-brain barrier. Peptides 2010; 31: 12: 2284-2288.

63. Fledelius C., Olsen G.S., Jensen A.B., Damgaard J., Vinterby A., Schiødt M., Nishimura E., Ribel U., Sturis J. The weight sparing effect of insulin detemir is associated with increased adiponectin levels and decreased adiposity in the diabetic ZDF rat. Diabetologia 2009; 52: Suppl 1: S285 (abstr 727).

64. Haluzik M., Parizkova J., Haluzik M.M. Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol Res 2004; 53: 2: 123-129.

65. Boden G., Laakso M. Lipids and glucose in type 2 diabetes: what is the cause and effect? Diabet Care 2004; 27: 9: 2253-2259.

66. Jung C.H., Rhee E.J., Choi J.H., Bae J.C., Yoo S.H., Kim W.J., Park C.Y., Mok J.O., Kim C.H., Lee W.Y., Oh K.W., Park S.W., Kim S.W. The relationship of adiponectin/leptin ratio with homeostasis model assessment insulin resistance index and metabolic syndrome in apparently healthy korean male adults. Korean Diabet J 2010; 34: 4: 237-243.

67. Ueno N., Inui A., Iwamoto M., Kaga T., Asakawa A., Okita M., Fujimiya M., Nakajima Y., Ohmoto Y., Ohnaka M., Nakaya Y., Miyazaki J.I., Kasuga M. Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology 1999; 117: 1427-1432.

68. Batterham R.L., Cohen M.A., Ellis S.M., Le Roux C.W., Withers D.J., Frost G.S., Ghatei M.A., Bloom S.R. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941-948.

69. Meier U., Gressner A.M. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004; 50: 1511-1525.

70. Liu S., Liu R., Chiang Y.T., Song L., Li X., Jin T., Wang Q. Insulin detemir enhances proglucagon gene expression in the intestinal L cells via stimulating Β-catenin and CREB activities. Am J Physiol Endocrinol Metabol 2012; 303: 6: E740-E751.

71. Hollander P., Raslova K., Skjøth T.V., Råstam J., Liutkus J.F. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Diabet Obes Metabol 2011; 13: 3: 268-275.

72. DeVries J.H., Bain S.C., Rodbard H.W., Seufert J., D'Alessio D., Thomsen A.B., Zychma M., Rosenstock J. Liraglutide-Detemir Study Group. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabet Care 2012; 35: 7: 1446-1454.

73. Vilsbøll T., Rosenstock J., Yki-Järvinen H., Cefalu W.T., Chen Y., Luo E., Musser B., Andryuk P.J., Ling Y., Kaufman K.D., Amatruda J.M., Engel S.S., Katz L. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabet Obes Metabol 2010; 12: 2: 167-177.

74. Fonseca V., Schweizer A., Albrecht D., Baron M.A., Chang I., Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50: 6: 1148-1155.

75. Hordern S.V., Wright J.E., Umpleby A.M., Shojaee-Moradie F., Amiss J., Russell-Jones D.L. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia 2005; 48: 420-426.

76. Bohm A., Staiger H., Hennige A.M., Haas C., Machicao F., Haring H.U. Effect of insulin detemir, compared to human insulin, on 3T3-L1 adipogenesis. Regul Pept 2008; 151: 1-3: 160-163.

77. Moore M.C., Smith M.S., Turney M.K., Boysen S., Williams P.E. Comparison of insulins detemir and glargine: effects on glucose disposal, hepatic glucose release and the central nervous system. Diabet Obes Metabol 2011; 13: 9: 832-840.

78. Nørgård K., Jensen T., Skøtt P. et al. Effect of insulin on renal haemodynamics and sodium handling in healthy subjects. Scand J Clin Lab Invest 1991; 51: 367-376.

79. Feldt-Rasmussen B., Mathiesen E.R., Deckert T., Giese J., Christensen N.J., Bent-Hansen L., Nielsen M.D. Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 8: 610-617.

80. Skøtt P., Hother-Nielsen O., Bruun N.E., Giese J., Nielsen M.D., Beck-Nielsen H., Parving H.H. Effects of insulin on kidney function and sodium excretion in healthy subjects. Diabetologia 1989; 32: 9: 694-699.

81. Stenvinkel P., Bolinder J., Alvestrand A. Effects of insulin on renal haemodynamics and the proximal and distal tubular sodium handling in healthy subjects. Diabetologia 1992; 35: 11: 1042-1048.

82. Hendriksen K.V., Jensen T., Oturai P., Feldt-Rasmussen B. Effects of insulin detemir and NPH insulin on renal handling of sodium, fluid retention and weight in type 2 diabetic patients. Diabetologia 2012; 55: 1: 46-50.